Priya Bansal, MD
Allergy & Immunology · Saint Charles, ILNPI 1811970486
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $871,023 of the $1,341,333 with a category attached, or 64.9%. 52 manufacturers reported payments, led by AstraZeneca at 33.2% of the total. 2025 is the largest year on record at $358,413, 2.3 times the $153,883 reported in 2019. Among allergy & immunology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,550 payments — averaging $526.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$445K
- CSL Behring$124K
- Regeneron Healthcare Solutions, Inc.$120K
- Takeda Pharmaceuticals U.S.A., Inc.$89K
- Sanofi$86K
- GSK$77K
- plus $400K from 46 others
What the payments were for
- Consulting fees$300,23122%
- Speaking & faculty fees$871,02365%
- Grants$5000%
- Travel & lodging$119,6699%
- Food & beverage$49,6224%
- Education$2880%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$163,139
- AIRSUPRA$150,905
- FASENRA$132,576
- TEZSPIRE$127,996
- Haegarda$65,441
- NUCALA$61,977
- CINRYZE$55,442
- RUCONEST$52,251
- EBGLYSS$34,037
- Andembry$33,075
- TAKHZYRO$26,488
- XOLAIR$26,041
- Odactra$24,378
- Rhapsido$20,670
- Xhance$18,425
- ProAir Digihaler$14,540
- AYVAKIT$13,791
- TRELEGY ELLIPTA$9,100
- DAWNZERA$8,691
- AirDuo RespiClick$7,168
How this compares
$1,341,333 in reported general payments places this provider in the 95th percentile of 161 allergy & immunology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TakhzyroLanadelumab-Flyo | 19 | $956,043 |
| SucraidSacrosidase | 13 | $143,511 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 70 | $70,779 |
| XhanceFluticasone Propionate | 30 | $44,180 |
| Arnuity ElliptaFluticasone Furoate | 60 | $19,699 |
| Breo ElliptaFluticasone/Vilanterol | 30 | $15,588 |
| Spiriva RespimatTiotropium Bromide | 22 | $15,148 |
| Advair HfaFluticasone Propion/Salmeterol | 15 | $10,279 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 30 | $6,871 |
| Epinephrine | 23 | $3,672 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $3,076 |
| Azelastine Hcl | 59 | $2,422 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 49 | $1,672 |
| Montelukast Sodium | 94 | $1,495 |
| Levocetirizine Dihydrochloride | 54 | $1,411 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Takhzyro | $88,678 | $956,04319 claims |
| QOL Medical, LLCSucraid | $599 | $143,51113 claims |
| GSKTrelegy Ellipta, Arnuity Ellipta, Breo Ellipta | $77,123 | $106,067160 claims |
| Optinose US, Inc.Xhance | $19,956 | $44,18030 claims |
| Boehringer IngelheimSpiriva Respimat | $215 | $15,14822 claims |
| Hikma Pharmaceuticals USAEpinephrine | $5,356 | $3,67223 claims |
| AstraZenecaSymbicort | $445,477 | $3,07613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 161 allergy & immunology providers in Illinois.
Other allergy & immunology in Saint Charles
- Dareen SiriNormal$1.5M
- Anju PetersChicago$563K
- Giselle MosnaimChicago$331K
- Patrick WinShiloh$258K
- Amanda SalihChicago$160K
- Rebecca HoffmanWilmette$160K
- Juanita MoraChicago$147K
- Sonali MajmudarAlgonquin$136K
- Zachary RubinElmhurst$133K
- Joyce RabbatMaywood$79K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.